|
Valoración de DCF de Immucell Corporation (ICCC)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
ImmuCell Corporation (ICCC) Bundle
¡Obtenga dominio sobre su análisis de valoración de Immucell Corporation (ICCC) con nuestra calculadora DCF de última generación! Antes de datos auténticos (ICCC), esta plantilla de Excel le permite modificar pronósticos y supuestos para calcular con precisión el valor intrínseco de Immucell Corporation.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.7 | 15.3 | 19.2 | 18.6 | 17.5 | 18.7 | 20.0 | 21.4 | 22.9 | 24.5 |
| Revenue Growth, % | 0 | 11.8 | 25.43 | -3.51 | -5.9 | 6.95 | 6.95 | 6.95 | 6.95 | 6.95 |
| EBITDA | 1.4 | 1.6 | 2.7 | .3 | -2.5 | .9 | .9 | 1.0 | 1.0 | 1.1 |
| EBITDA, % | 10.43 | 10.74 | 14.12 | 1.88 | -14.33 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 |
| Depreciation | 2.3 | 2.4 | 2.5 | 2.5 | 2.7 | 2.8 | 2.9 | 3.2 | 3.4 | 3.6 |
| Depreciation, % | 16.52 | 15.4 | 12.85 | 13.4 | 15.55 | 14.74 | 14.74 | 14.74 | 14.74 | 14.74 |
| EBIT | -.8 | -.7 | .2 | -2.1 | -5.2 | -1.9 | -2.0 | -2.2 | -2.3 | -2.5 |
| EBIT, % | -6.09 | -4.66 | 1.27 | -11.51 | -29.88 | -10.17 | -10.17 | -10.17 | -10.17 | -10.17 |
| Total Cash | 8.8 | 7.9 | 10.2 | 5.8 | 1.0 | 7.7 | 8.2 | 8.8 | 9.4 | 10.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.7 | 1.9 | 2.7 | 1.8 | 2.2 | 2.3 | 2.4 | 2.6 | 2.8 | 3.0 |
| Account Receivables, % | 12.23 | 12.15 | 14.14 | 9.7 | 12.51 | 12.14 | 12.14 | 12.14 | 12.14 | 12.14 |
| Inventories | 2.5 | 2.1 | 3.1 | 6.0 | 7.8 | 4.7 | 5.0 | 5.4 | 5.7 | 6.1 |
| Inventories, % | 18.35 | 13.64 | 16.06 | 32.52 | 44.71 | 25.06 | 25.06 | 25.06 | 25.06 | 25.06 |
| Accounts Payable | .4 | .6 | .7 | .8 | .9 | .7 | .8 | .9 | .9 | 1.0 |
| Accounts Payable, % | 2.93 | 3.93 | 3.87 | 4.25 | 5.01 | 4 | 4 | 4 | 4 | 4 |
| Capital Expenditure | -1.4 | -4.1 | -2.6 | -4.0 | -1.9 | -3.1 | -3.3 | -3.5 | -3.8 | -4.0 |
| Capital Expenditure, % | -10.14 | -26.55 | -13.56 | -21.41 | -10.83 | -16.5 | -16.5 | -16.5 | -16.5 | -16.5 |
| Tax Rate, % | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 | -0.08019104 |
| EBITAT | -.9 | -.7 | .3 | -2.1 | -5.2 | -1.9 | -2.0 | -2.2 | -2.3 | -2.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3.8 | -2.0 | -1.6 | -5.6 | -6.5 | .7 | -2.8 | -3.0 | -3.2 | -3.4 |
| WACC, % | 6.32 | 6.31 | 6.32 | 6.32 | 6.32 | 6.32 | 6.32 | 6.32 | 6.32 | 6.32 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -9.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4 | |||||||||
| Terminal Value | -81 | |||||||||
| Present Terminal Value | -60 | |||||||||
| Enterprise Value | -69 | |||||||||
| Net Debt | 16 | |||||||||
| Equity Value | -85 | |||||||||
| Diluted Shares Outstanding, MM | 8 | |||||||||
| Equity Value Per Share | -10.96 |
What You Will Get
- Real ICCC Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess ImmuCell's future performance.
- User-Friendly Design: Designed for professionals while remaining user-friendly for newcomers.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, EBITDA %, and capital expenditures tailored to ImmuCell Corporation (ICCC).
- Instant DCF Valuation: Effortlessly computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Accuracy: Leverages ImmuCell's actual financial data for credible valuation results.
- Simplified Scenario Analysis: Evaluate various assumptions and analyze results with ease.
- Efficiency Boosting Tool: Avoid the complexities of constructing intricate valuation models from the ground up.
How It Works
- Download: Obtain the pre-prepared Excel file containing ImmuCell Corporation’s (ICCC) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and instantly compare the results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose This Calculator for ImmuCell Corporation (ICCC)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for ImmuCell Corporation (ICCC).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for ImmuCell Corporation (ICCC).
- Detailed Insights: Automatically computes ImmuCell Corporation’s (ICCC) intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on ImmuCell Corporation (ICCC).
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessments of ImmuCell Corporation (ICCC).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients focused on ImmuCell Corporation (ICCC) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology companies like ImmuCell Corporation (ICCC) are appraised in the market.
What the Template Contains
- Pre-Filled Data: Includes ImmuCell Corporation's historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze ImmuCell Corporation's profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.